AHR Stock Forecast & Price Target

American Healthcare REIT is supported by strong organic growth in its core Integrated Senior Health Campuses and SHOP segments, with Trilogy and traditional SHOP benefiting from favorable supply-demand dynamics, higher-acuity private-pay mix, and pricing power that can lift margins. The company’s acquisition engine adds further upside, as more than $2.4B of closed and awarded investments, including the Kensington portfolio and additional SHOP deals, are expected to be accretive at attractive high-5% to low-6% yields while expanding scale. Its balance sheet is also a plus, with net debt-to-EBITDA at 2.5x as of 2Q26, over $2B of available liquidity, and sufficient capital to fund the pipeline while preserving flexibility.

American Healthcare REIT is trading at a 4.7% implied cap rate, materially below the 6.1%-6.2% healthcare average and the 7.0%-7.3% REIT average, which suggests the stock already embeds a premium valuation despite elevated operating risk. Its fundamentals are heavily dependent on Trilogy, which generates over half of NOI, while roughly half of Trilogy NOI comes from skilled nursing beds, leaving results exposed to reimbursement pressure, Medicaid cuts, labor constraints, and headline risk. Although 2026 NFFO guidance is $2.03-$2.09 per share and expected investments are about $2.7 billion, the combination of regulatory uncertainty, tenant concentration, and higher G&A expense supports a negative outlook.